Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

234
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

766
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
766
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

260
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
260

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opicapone in Parkinson's patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study.

Clinical parkinsonism & related disorders·2026
Same author

A clinimetric evaluation of the problem behaviors assessment short form (PBA-s) within the context of the Huntington's disease integrated staging system (HD-ISS).

Journal of Huntington's disease·2026
Same author

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Validation of the Norwegian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Clinical parkinsonism & related disorders·2026
Same author

CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge Gaps.

Neurology·2026
Same author

The persisting puzzle of OFF time in advanced Parkinson's disease.

Brain : a journal of neurology·2026

Related Experiment Video

Updated: Jul 4, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K

Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.

Peter A LeWitt1, Glenn T Stebbins2, Kenneth Vielsted Christensen3

  • 1Department of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, Michigan, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|February 5, 2024
PubMed
Summary

This study found that combining buspirone and zolmitriptan effectively reduced Parkinson's disease (PD) dyskinesia without worsening motor symptoms. This combination therapy shows promise for managing levodopa-induced dyskinesia in PD patients.

Keywords:
Parkinson's diseasebuspironedyskinesiazolmitriptan

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.1K

Related Experiment Videos

Last Updated: Jul 4, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • Preclinical studies suggest synergistic effects of buspirone (5-HT1A agonist) and zolmitriptan (5-HT1B/1D agonist) in reducing dyskinesia.
  • Levodopa-induced dyskinesia is a common and disabling motor complication in Parkinson's disease (PD).

Purpose of the Study:

  • To evaluate the therapeutic potential of a fixed-dose combination of buspirone and zolmitriptan.
  • To assess the efficacy and safety of this combination in PD patients experiencing levodopa-induced dyskinesia.

Main Methods:

  • A single-center, randomized, placebo-controlled, two-way crossover study (NCT02439203).
  • Involved 30 PD patients with moderately disabling peak-effect dyskinesia.
  • Administered a fixed-dose regimen of buspirone/zolmitriptan (10/1.25 mg three times daily) for seven days.

Main Results:

  • Buspirone/zolmitriptan significantly reduced dyskinesia scores (Abnormal Involuntary Movement Scale) compared to placebo (mean difference: -4.2).
  • No significant worsening of motor function was observed, as measured by Unified Parkinson's Disease Rating Scale (UPDRS) Part III (ON) scores (mean difference: 0.6).
  • No serious adverse events were reported during the study.

Conclusions:

  • The addition of buspirone/zolmitriptan to existing PD medication significantly reduced dyskinesia severity.
  • This combination therapy offers a potential new treatment strategy for managing dyskinesia in Parkinson's disease.
  • The findings support buspirone/zolmitriptan as a viable option for improving motor complications in PD without compromising motor control.